tirzepatide renal impairment (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide and Chronic Kidney Disease:

We are here to help you feel your best and reaching a healthy weight can play a role

Zerrouki D, et al

With promotional pricing starting around $114 per month for oral semaglutide and injectable options beginning at $233-$263 monthly, the platform targets individuals who are seeking alternatives to branded medications or traditional in-person weight management programs

Susan Lovelle, an expert in lifestyle medicine and holistic health, this trend isnt just about weightIts about the increasing prevalence of related conditions like cardiovascular disease, Type 2 diabetes, and hormonally driven cancers. In her recent presentation for AccessLive, our educational webinar series for physicians, she stresses that these challenges are compounded by lifestyle factors such as chronic stress, poor diet, and insufficient sleep, all of which contribute to systemic inflammation and metabolic imbalances

Thats expected to grow by nearly 50% to 24 million Americans by 2035

However it is worth noting that one patient presented with a severe hyperglycemia at follow-up (A1c = 18.4%)